Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C

Authors


Correspondence
Isabel Zvibel, Gastroenterology Institute and Liver Unit, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv 64239, Israel
Tel: +972 3 697 4481
Fax: +972 3 697 4226
e-mail: isab@tasmc.health.gov.il

Abstract

Background and Aims: Syndecan 1 (CD 138) is a cell surface proteoglycan shed by cells in several pathological conditions, including wound healing. The aim of this study was to test whether CD138 could serve as a non-invasive marker for detection of liver fibrosis and thereby reduce the need for liver biopsy.

Patients and Methods: An estimation set of 134 patients and a validation set of 67 patients with chronic hepatitis C were studied. There were 80 normal healthy volunteers. Patients were staged according to liver biopsies (Metavir fibrosis staging, stage F0, n=35; F1, n=40; F2, n=37, F3, n=39; F4, n=51). Serum CD138 levels were retrospectively measured by enzyme-linked immunoabsorbent assay the same day of the liver biopsy. The primary endpoints were the diagnostic values of CD138 for F2–F4, F3–F4 and F4.

Results: Respective areas under receiver operating characteristic curve of CD138 for F2–F4, F3–F4 and F4 diagnosis were 0.82, 0.76 and 0.81. CD138 had a positive predictive value of 82% for F2–F4 diagnosis and a high negative predictive value (86%) and specificity (84%) for exclusion of F4.

Conclusion: CD138 is a new simple non-invasive marker for predicting liver fibrosis in patients with chronic hepatitis C. The relevance of this marker in combination with other fibrosis markers should be explored.

Ancillary